American Association for Cancer Research
Browse
00085472can072153-sup-suppl_figs_and_tables.pdf (4.48 MB)

Supplementary Figures 1-5, Tables 1-4 from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies

Download (4.48 MB)
journal contribution
posted on 2023-03-30, 17:28 authored by Sarah V. Bradley, Mitchell R. Smith, Teresa S. Hyun, Peter C. Lucas, Lina Li, Danielle Antonuk, Indira Joshi, Fang Jin, Theodora S. Ross
Supplementary Figures 1-5, Tables 1-4 from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies

History

ARTICLE ABSTRACT

Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non–Hodgkin's and Hodgkin's lymphomas and that patients with lymphoid malignancies frequently had anti-HIP1 antibodies in their serum. Moreover, p53-deficient mice with B-cell lymphomas were 13 times more likely to have anti-HIP1 antibodies in their serum than control mice. Furthermore, transgenic overexpression of HIP1 was associated with the development of lymphoid neoplasms. The HIP1 protein was induced by activation of the nuclear factor-κB pathway, which is frequently activated in lymphoid malignancies. These data identify HIP1 as a new marker of lymphoid malignancies that contributes to the transformation of lymphoid cells in vivo. [Cancer Res 2007;67(18):8923–31]

Usage metrics

    Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC